Matthew H Herynk
Overview
Explore the profile of Matthew H Herynk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
712
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Patel S, Herynk M, Cascone T, Saigal B, Nilsson M, Tran H, et al.
J Thorac Oncol
. 2021 Jul;
16(12):2051-2064.
PMID: 34311109
Introduction: Subgroup analyses from clinical studies have suggested that among patients with metastatic NSCLC receiving chemotherapy, females may derive less benefit from the addition of the vascular endothelial growth factor...
2.
Nilsson M, Robichaux J, Herynk M, Cascone T, Le X, Elamin Y, et al.
J Thorac Oncol
. 2020 Dec;
16(3):439-451.
PMID: 33309987
Introduction: The treatment of patients with EGFR-mutant NSCLC with vascular endothelial growth factor (VEGF) inhibitors in combination with EGFR inhibitors provides a greater benefit than EGFR inhibition alone, suggesting that...
3.
Tetuan T, Ohm R, Herynk M, Ebberts M, Wendling T, Mosier M
J Nurs Adm
. 2014 Apr;
44(5):270-5.
PMID: 24759199
Objective: The aim of this study was to determine the effectiveness of the nurse-run annual wellness visit (AWV) in improving adherence to cancer screening recommendations for colonoscopies and/or mammograms. Background:...
4.
Selever J, Gu G, Lewis M, Beyer A, Herynk M, Covington K, et al.
Clin Cancer Res
. 2011 Sep;
17(20):6510-21.
PMID: 21878538
Purpose: Tamoxifen (Tam) is the most prescribed hormonal agent for treatment of estrogen receptor α (ERα)-positive breast cancer patients. Using microarray analysis, we observed that metastatic breast tumors resistant to...
5.
Herynk M, Selever J, Thirugnanasampanthan J, Cui Y, Fuqua S
Cancer Treat Res
. 2011 Apr;
147:1-16.
PMID: 21461833
No abstract available.
6.
Cascone T, Herynk M, Xu L, Du Z, Kadara H, Nilsson M, et al.
J Clin Invest
. 2011 Mar;
121(4):1313-28.
PMID: 21436589
Angiogenesis is critical for tumor growth and metastasis, and several inhibitors of angiogenesis are currently in clinical use for the treatment of cancer. However, not all patients benefit from antiangiogenic...
7.
Herynk M, Hopp T, Cui Y, Niu A, Corona-Rodriguez A, Fuqua S
Breast Cancer Res Treat
. 2009 Oct;
122(2):381-93.
PMID: 19842032
Estrogen receptor alpha (ERalpha) is highly regulated through multiple mechanisms including cell signaling, posttranslational modifications, and protein-protein interactions. We have previously identified a K303R ERalpha mutation within the hinge region...
8.
Raso M, Behrens C, Herynk M, Liu S, Prudkin L, Ozburn N, et al.
Clin Cancer Res
. 2009 Aug;
15(17):5359-68.
PMID: 19706809
Purpose: To determine the frequency of estrogen receptor alpha and beta and progesterone receptor protein immunohistochemical expression in a large set of non-small cell lung carcinoma (NSCLC) specimens and to...
9.
De Amicis F, Thirugnansampanthan J, Cui Y, Selever J, Beyer A, Parra I, et al.
Breast Cancer Res Treat
. 2009 Jun;
121(1):1-11.
PMID: 19533338
Although the androgen receptor (AR) is a known clinical target in prostate cancer, little is known about its possible role in breast cancer. We have investigated the role of AR...
10.
Barone I, Cui Y, Herynk M, Corona-Rodriguez A, Giordano C, Selever J, et al.
Cancer Res
. 2009 Jun;
69(11):4724-32.
PMID: 19487288
Aromatase inhibitors (AI) are rapidly becoming the first choice for hormonal treatment of estrogen receptor-alpha (ERalpha)-positive breast cancer in postmenopausal women. However, de novo and acquired resistance frequently occurs. We...